Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Foundation Medicine

< Previous 1 2 Next >
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Selected Marketed and Pipeline Treatments
From Foundation Medicine
Via Business Wire
Foundation Medicine Expands Monitoring Portfolio with Launch of FoundationOne®Monitor
From Foundation Medicine
Via Business Wire
FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer
From Foundation Medicine
Via Business Wire
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
From Foundation Medicine
Via Business Wire
Foundation Medicine to Share 10 Abstracts at AACR23 Demonstrating the Unique Capabilities of Its Molecular Profiling Tests to Advance Precision Cancer Care
From Foundation Medicine
Via Business Wire
Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
From Foundation Medicine
Via Business Wire
UnitedHealthcare Provides Commercial Coverage for FoundationOne®CDx and FoundationOne®Liquid CDx in Multiple Companion Diagnostic Indications
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Companion Diagnostic for XPOVIO® (selinexor)
From Foundation Medicine
Via Business Wire
Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use
From Foundation Medicine
Via Business Wire
FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)
From Foundation Medicine
Via Business Wire
Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients
From Foundation Medicine
Via Business Wire
Foundation Medicine Launches FoundationReport+™, a New Digital Reporting Experience to Streamline Precision Cancer Care
From Foundation Medicine
Via Business Wire
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
From Foundation Medicine
Via Business Wire
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
From Foundation Medicine
Via Business Wire
Tickers RLAY
Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care
From Foundation Medicine
Via Business Wire
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer
From Foundation Medicine
Via Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for Rozlytrek® (entrectinib)
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Strategic Collaboration with Arvinas
From Foundation Medicine
Via Business Wire
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy
From Foundation Medicine
Via Business Wire
Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual Meeting Highlighting How Molecular Profiling is Helping to Shape the Future of Personalized Cancer Care
From Foundation Medicine
Via Business Wire
Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care
From Foundation Medicine
Via Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer
From Foundation Medicine
Via Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors
From Foundation Medicine
Via Business Wire
Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration
From Foundation Medicine
Via Business Wire
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
From Foundation Medicine
Via Business Wire
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
From Foundation Medicine
Via Business Wire
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services
From Foundation Medicine
Via Business Wire
Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer
From Foundation Medicine
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.